Venous thromboembolism and bleeding after total knee and hip arthroplasty

Summary

The impact of venous thromboembolism (VTE) and bleeding in patients undergoing major joint surgery has not been thoroughly studied. The Spanish National Discharge Database during the years 2005–2006 was used to assess the frequency and clinical impact of VTE and bleeding after elective total knee (TKA) or hip (THA) arthroplasty. Of 58,037 patients undergoing TKA, 0.18% (95% confidence interval [CI]: 0.15–0.22) were diagnosed with pulmonary embolism (PE), 0.57% (95% CI: 0.51–0.63) with deep-vein thrombosis (DVT), 1.20% (95% CI: 1.12–1.30) had bleeding complications, and 0.09% (95% CI: 0.07–0.12) died. Of 54 patients who died, 20.4% (95% CI: 10.7–35.4) had been diagnosed with PE, 3.70% (95% CI: 0.63–11.7) with DVT, and 13.0% (95% CI: 5.67–25.6) had bled. Of 31,769 patients undergoing elective THA, 0.23% (95% CI: 0.18–0.29) were diagnosed with PE, 0.44% (95% CI: 0.37–0.52) with DVT, 1.21% (95% CI: 1.10–1.34) bled, and 0.16% (95% CI: 0.12–0.21) died. Of 52 patients who died, 13.5% (95% CI: 6.08–24.8) had been diagnosed with PE, and 9.61% (95% CI: 3.52–21.3) had bled. On multivariable analysis, PE (odds ratio [OR]: 157; 95% CI: 75–328), DVT (OR: 6.3; 95% CI: 1.5–27) and bleeding (OR: 8.5; 95% CI: 3.6–20) were independent predictors for death after TKA. After THA, only PE (OR: 65; 95% CI: 26–160) and bleeding (OR: 6.4; 95% CI: 2.3–17) predicted the risk for death. Bleeding, DVT, and PE, arising after TKA were all independent predictors for death. Their increase in risk was, however, substantially higher for PE. After THA, only PE and bleeding independently predicted death.

Keywords

Prophylaxis - surgery - orthopaedics - venous thrombosis - pulmonary embolism

• References

• 1 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism. American College of Chest Physicians evidence- based clinical practice guidelines (8^th Edition). Chest 2008; 6: 381S-453S.
• 2 American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Adopted by the American Academy of Orthopaedic Surgeons Board of Directors May 2007. Available at: www.aaos.org/research/guidelines/PE_guideline.pdf Accessed March 30, 2009.
• 3 Haas SB, Barrack MPH, Westrich G. et al. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2008; 90: 2764-2780.
• 4 International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health service, US Dept of Health and Human Services; 1988
• 5 Johnson R, Green JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop Relat Res 1977; 127: 123-132.
• 6 Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop 1991; 273: 125-130.
• 7 Huber O, Bounameaux H, Borst F. et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-313.
• 8 Sharrock NE, Cazan MG, Hargett MJL. et al. Changes in mortality after total hip and knee arthroplasty over a ten-year period. Anesth Analg 1995; 80: 242-248.
• 9 White RH, Romano PS, Zhou H. et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
• 10 Rahme E, Dasgupta K, Burman M. et al. Postdischarge thromboprophylaxis and mortality risk after hip- or knee-replacement surgery. CMAJ 2008; 178: 1545-1554.
• 11 Brotman DJ, Jaffer AK, Hurbanek JG. et al. Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. Thromb Haemost 2004; 92: 1012-1017.
• 12 Memtsoudis SG, Besculides MC, Gaber L. et al. Risk factors for pulmonary embolism after hip and knee arthroplasty: A population-based study. Intern Orthopaedics 2009; 33: 1739-1745.
• 13 Monreal M, Peidró L, Resines C. et al. NETCOT Investigators.. Limited diagnostic workup for deep vein thrombosis after major joint surgery: Findings from a prospective, multicentre, cohort study. Thromb Haemost 2008; 99: 1112-1115.
• 14 Gendelman DLD, Maheshwari AV, Boutary M. et al. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg (Am) 2007; 89: 264-257.
• 15 Pedersen AB, Sorensen HT, Mehnert F. et al. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg (Am) 2010; 92: 2156-2164.
• 16 Burnett RSJ, Clohisy JC, Wright RW. et al. Failure of the American College of Chest Physicians-1A protocol for Lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty 2007; 22: 317-324.
• 17 Qadan M, Tyson M, McCafferty MH. et al. Venous thromboembolism in elective operations: balancing the choices. Surgery 2008; 144: 654-661.
• 18 Sharrock NE, Gonzalez Della Valle A, Go G. et al. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 2008; 466: 714-721.
• 19 Warwick D, Dahl OE, Fisher WD. Orthopaedic thromboprophylaxis. Limitations of current guidelines. J Bone Joint Surg (Br) 2008; 90: 127-132.
• 20 Eikelboom JW, Karthikeyan G, Fagel N. et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ. What are the implications for clinicians and patients? Chest 2009; 135: 513-520.
• 21 Cushner FD, Nett MP. Unanswered questions, unmet needs in venous thromboprophylaxis. Orthopedics 2009; 32 (Suppl. 12) 62-66.
• 22 Lachiewicz PF. Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty. Orthopedics 2009; 32 (Suppl. 12) 74-78.
• 23 Struijk-Mulder MC, Ettema HB, Verheyen CC. et al. Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost 2010; 8: 678-683.
• 24 Eriksson BI, Borris LC, Friedman RJ. et al. RECORD1 Study Group.. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
• 25 Lassen MR, Ageno W, Borris LC. et al. RECORD3 Investigators.. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
• 26 Lotke PA. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008; 359: 2174.